scholarly journals Reference ranges for serum protein fractions as determined by capillary zone electrophoresis.

2001 ◽  
Vol 45 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Hiroshi Ihara ◽  
Natsuko Toya ◽  
Takashi Kakinoki ◽  
Asuka Tani ◽  
Yutaka Aoki ◽  
...  
Keyword(s):  
Capillary Zone Electrophoresis ◽  
Serum Protein ◽  
Protein Fractions ◽  
Reference Ranges ◽  
Zone Electrophoresis ◽  
Capillary Zone

Case report: Interference from isatuximab on serum protein electrophoresis prevented demonstration of complete remission in a myeloma patient

2021 ◽  
pp. 000456322110620
Author(s):  
Rachel D Wheeler ◽  
Micsha V Costa ◽  
Asante Crichlow ◽  
Fenella Willis ◽  
Yasmin Reyal ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Complete Remission ◽  
Capillary Zone Electrophoresis ◽  
Serum Protein ◽  
Plasma Cells ◽  
Survival Rates ◽  
Protein Electrophoresis ◽  
Serum Protein Electrophoresis ◽  
Zone Electrophoresis ◽  
Capillary Zone

Multiple myeloma is a haematological cancer caused by malignant plasma cells in the bone marrow that can result in organ dysfunction and death. Recent novel treatments have contributed to improved survival rates, including monoclonal antibody therapies that target the CD38 protein on the surface of plasma cells. Anti-CD38 therapies are IgG kappa monoclonal antibodies that are given in doses high enough for the drug to be visible on serum protein electrophoresis as a small paraprotein. We present a case where isatuximab, the most recent anti-CD38 monoclonal antibody to be approved for treatment of myeloma, obscured the patient’s paraprotein on gel immunofixation, so that complete remission could not be demonstrated. This was resolved using the isatuximab Hydrashift assay. The interference on gel immunofixation was unexpected because isatuximab migrated in a position distinct from the patient’s paraprotein on capillary zone electrophoresis. We demonstrate the surprising finding that isatuximab migrates in a different position on gel electrophoresis compared to capillary zone electrophoresis. It is vital that laboratories are aware of the possible interference on electrophoresis from anti-CD38 monoclonal antibody therapies, and are able to recognise these drugs on protein electrophoresis. The difference in isatuximab’s electrophoretic mobility on capillary and gel protein electrophoresis makes this particularly challenging. Laboratories should have a strategy for alternative analyses in the event that the drugs interfere with assessment of the patient’s paraprotein.

Routine serum protein analysis by capillary zone electrophoresis: Clinical evaluation

1997 ◽  
Vol 45 (1) ◽  
pp. 390-395 ◽  
Author(s):  
R. Lehmann ◽  
M. Koch ◽  
W. Voelter ◽  
H. U. Häring ◽  
H. M. Liebich
Keyword(s):  
Capillary Zone Electrophoresis ◽  
Serum Protein ◽  
Clinical Evaluation ◽  
Protein Analysis ◽  
Zone Electrophoresis ◽  
Capillary Zone
Sign in / Sign up

Export Citation Format

Share Document